Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : FDA : J&J Unit Recalls Potentially Flammable Bone Putty

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/22/2012 | 12:13am CET
   By Ben Fox Rubin 
 

The Food and Drug Administration said Johnson & Johnson (JNJ) unit Synthes last month initiated a recall on certain lots of bone putty, saying the medical product could catch fire during surgery.

The FDA gave the recall a Class I designation, its most serious type of recall.

The regulator said Synthes in early July issued a medical device recall letter, asking medical facilities to examine their inventories and immediately stop using specific lots of the putty. The product, called a hemostatic bone putty, is used to stop bone bleeding by creating a physical barrier along the edges of bones that have been damaged by trauma or cut during surgery.

The FDA said the putty could ignite under some conditions if contacted with certain surgical equipment.

The lots recalled were manufactured between July 6, 2011, and Dec. 14, 2011, and were distributed from Dec. 22, 2011, to June 25, 2012.

J&J in June completed its $19.7 billion purchase of medical-device maker Synthes. The health-care giant has worked to tackle a range of problem products, such as the bottles of children's Tylenol and other popular over-the-counter medicines, as well as some contact lenses and certain hip implants, that the company recalled due to manufacturing problems.

The company's shares closed Tuesday at $67.78 and were up 15 cents after hours. The stock is up 3.4% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 JOHNSON & JOHNSON : The Woodrow Wilson Center (WWC) - Discussion
12/02 HIP DAMAGES : Jury tells J&J to pay another $1 billion
12/02 JOHNSON & JOHNSON : to pay $1 billion for faulty hip implants
12/02 JOHNSON & JOHNSON : J&J ordered to pay record $1 billion for faulty hip implants
12/02 JOHNSON & JOHNSON : Dallas Jury Returns $1 Billion-Plus Verdict in Defective DeP..
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/29 WPP : Acquires US Company Promotion Execution Partners
11/28 Global Hepatitis C Drug Market - Merck & Co, Kenilworth, Roche, Basel GlaxoSm..
More news
Sector news : Pharmaceuticals - NEC
12/02 Pharma execs weigh in on possible changes under Trump
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
12/01 GLAXOSMITHKLINE : GSK biotech asthma drug wins UK approval after extra price cut
12/01 PERRIGO : Cohen's SAC Capital in $135 million settlement with Elan investors
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/02 J&J Actelion bid reportedly tops $250/share
12/02 GILEAD : M&A Coming Soon
12/02 WALL STREET BREAKFAST : Non-Farm Payrolls In Focus
12/01 Johnson & Johnson hit with $1B-plus jury verdict on faulty hip implants
12/01 With 2016 Nearing A Close, Our Dividend Growth Portfolio Is Up Almost 10%
Advertisement
Financials ($)
Sales 2016 72 061 M
EBIT 2016 22 017 M
Net income 2016 16 371 M
Finance 2016 18 064 M
Yield 2016 2,80%
P/E ratio 2016 18,94
P/E ratio 2017 16,70
EV / Sales 2016 3,98x
EV / Sales 2017 3,70x
Capitalization 304 591 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 126 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON9.00%304 591
PFIZER INC.-2.01%191 942
ROCHE HOLDING LTD.-19.61%188 878
NOVARTIS AG-19.07%178 737
MERCK & CO., INC.15.85%168 544
SANOFI-4.20%103 510
More Results